In the tumor rebiopsy, 94.2% (33/35) were positive for EGFR mutations, including 8 (22.9%; 8/35) L858R mutations, 6 (17.1%; 6/35) L858R combined with T790M mutations, 10 (28.6%; 10/35) exon 19 deletions, 8 (22.9%; 8/35) exon 19 deletions combined with T790M mutations and 1 (2.9%; 1/35) T790M mutation only. This evidence concerns the gene EGFR and neoplasm.